Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR‐TKIs and mTOR inhibitor

Angiogenesis and immunosuppression work hand‐in‐hand in the renal cell carcinoma (RCC) microenvironment. Tumor growth is associated with impaired antitumor immune response in RCC, which involves T cells, natural killer cells, dendritic cells (DCs) and macrophages. Vascular endothelial growth factor...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cancer 2014-06, Vol.134 (12), p.2772-2777
Main Authors: Santoni, Matteo, Berardi, Rossana, Amantini, Consuelo, Burattini, Luciano, Santini, Daniele, Santoni, Giorgio, Cascinu, Stefano
Format: Article
Language:English
Subjects:
Adaptive Immunity - immunology
Angiogenesis
Angiogenesis Inhibitors - therapeutic use
Biological and medical sciences
Cancer
Carcinoma, Renal Cell - immunology
Cell Movement - immunology
Cell Proliferation
Chemotherapy
Dendritic Cells - immunology
Humans
immune cells
Immunosuppression
Immunotherapy
Kidney cancer
Kidney Neoplasms - immunology
Kidneys
Medical research
Medical sciences
Metastasis
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
natural and adaptive immunity
Neoplasm Invasiveness - immunology
Neoplasm Metastasis - immunology
Neovascularization, Pathologic - immunology
Nephrology. Urinary tract diseases
Neutrophil Activation - immunology
Neutrophils - immunology
Protein Kinase Inhibitors - therapeutic use
Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors
renal cell carcinoma
T-Lymphocytes - immunology
targeted therapy
TOR Serine-Threonine Kinases - antagonists & inhibitors
Tumors
Tumors of the urinary system
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Angiogenesis and immunosuppression work hand‐in‐hand in the renal cell carcinoma (RCC) microenvironment. Tumor growth is associated with impaired antitumor immune response in RCC, which involves T cells, natural killer cells, dendritic cells (DCs) and macrophages. Vascular endothelial growth factor receptor (VEGFR), such as sorafenib, sunitinib, pazopanib and axitinib, and mammalian target of rapamycin (mTOR) inhibitors, such as temsirolimus and everolimus, do exert both antiangiogenic and immunomodulatory functions. Indeed, these agents affect neutrophil migration, as well as T lymphocyte‐DC cross‐talk, DC maturation and immune cell metabolism and reactivity. In this review, we overview the essential role of innate and adaptive immune response in RCC proliferation, invasion and metastasis and the relationship between tumor‐associated immune cells and the response to targeted agents approved for the treatment of metastatic RCC.
ISSN:0020-7136
1097-0215
DOI:10.1002/ijc.28503